vykat xr
vykat xr: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| SOLENO THERAPEUTICS INC (SLNO) | Approved |
Clinical Trials (1)
An Observational Study of VYKAT™ XR (Diazoxide Choline Extended-Release Tablets) in Patients With Prader-Willi Syndrome (PWS)
FDA Decisions
Frequently asked questions
Who is developing vykat xr?
vykat xr is being developed by SOLENO THERAPEUTICS INC.
How many clinical trials involve vykat xr?
BioSniper tracks 1 clinical trial involving vykat xr.
What is vykat xr's latest FDA decision?
The most recent tracked FDA decision for vykat xr is Approval for 1 INDICATIONS AND USAGE VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). ( 1 ), dated March 26, 2025.
Get deeper analysis on vykat xr
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis